Sebastian Guth Named to PharmaVoice 100 List of Most Inspiring Leaders for 2022
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that Sebastian Guth, president of Bayer Pharmaceuticals, Americas and member of the global Pharmaceutical Executive Committee, has been named to the PharmaVoice 100, an annual list of the most inspiring leaders in the life sciences industry, representing innovators; disrupters; and champions of diversity, equity and inclusion.
A 20-year veteran of the pharmaceutical industry, Guth oversees operations for Bayer Pharmaceuticals in the United States, the company’s largest market, as well as Canada and Latin America. He is consistently recognized as a visionary and inspirational leader committed to bringing forth new healthcare solutions and providing equitable access to healthcare for all people.
“I am incredibly proud to lead our employees across the Americas in advancing the meaningful work we do each day,” said Guth. “Each of us is deeply committed to helping all people live healthier lives. It’s an honor to be recognized among my peers as a PharmaVoice 100 recipient.”
Since assuming his role nearly four years ago, Guth and his team have accelerated growth of the North American business, reaching $4.86 billion in pharmaceutical sales last year. He guided a cultural transformation of the business that grew employee engagement by 18 percent during his first two years as president; and fostered diversity within his leadership team, moving from 15 percent to a 50 percent-led female team today.
Guth serves as a member of the Board of Trustees for Children’s Aid, a New York City-based organization that works to help children in poverty succeed. He has championed many important initiatives, including the expansion of Bayer’s partnership with Direct Relief, a non-profit humanitarian organization to fund health clinics across the United States to provide education and access to reproductive health services for underserved women. Guth has also supported Bayer’s leadership position in several population health organizations on the company’s behalf, including the Population Health Alliance, Pharmacy Quality Alliance and the National Alliance of Healthcare Purchaser Coalitions.
“Sebastian is a transformative leader who believes that culture is the glue that keeps everyone together and is what turns a good organization into a great organization,” said Simon Rosof, vice president of oncology sales and marketing in North America, who nominated Guth and has worked with him across many roles. “When he sees an opportunity to advance patient care, he rallies the organization around him to act with speed, resolve and total commitment to the people we serve.”
On September 15, Guth will join the 2022 PharmaVoice 100 celebration as a panelist during its virtual event, The Next Era of Leadership, from 10-11 a.m. ET. Register for the event at PharmaVoice 100 Celebration: The Next Era of Leadership (industrydive.com).
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.
Follow Guth on LinkedIn: https://www.linkedin.com/in/sebastian-guth-4a83175a/
Find more information at https://pharma.bayer.com/
Follow Bayer on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact for media inquiries:
Sue Ann Pentecost
+1 910 221 6446